Business
Renalytix Reports Full Year Fiscal 2021 Results
Renalytix Reports Full Year Fiscal 2021 Results.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7882P\n Renalytix PLC\n 21 October 2021\n \n \n \n \n Renalytix plc\n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Renalytix Reports Full Year Fiscal 2021 Results\n \n \n \n \n \n \n LONDON and SALT LAKE CITY, October 21, 2021 \n \n - \n Renalytix plc \n (NASDAQ: RNLX), \n (LSE\n : RENX) \n an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care\n , \n announces its results for the twelve months ended 30 June 2021. \n \n \n \n \n \n Highlights: \n \n \n \n \n \n Regulatory & Reimbursement\n \n \n · \n Government-wide contract granted by the U.S. General Services Administration for KidneyIntelXTM testing services at $950 per reportable result; applies to more than 140 U.S. government departments, agencies, and affiliates including U.S. Veterans Administration (VA), Department of Defense military branches (Army, Navy, Air Force, and Marines), and Indian Health Services\n \n \n · \n Accepted provider in 27 Medicaid state programs (including post-period approvals) with additional applications pending\n \n \n · \n Ongoing process with Medicare Contractor organizations for Medicare local coverage\n \n \n · \n Positive coverage determinations from 20 regional and local private health insurance payors to date including the first Blue Cross Blue Shield coverage contract and coverage with HealthFirst, one of New York State's largest not-for-profit health insurance companies with over 1.5 million members\n \n \n · \n Ongoing process with FDA towards anticipated De Novo marketing authorization under Breakthrough Device designation\n \n \n · \n Full CLIA certification of Salt Lake City laboratory facility \n \n \n \n \n \n Commercial / Partnerships\n \n \n · \n KidneyIntelX launched within the Mount Sinai Health System, validating the electronic health record (EHR) integrated care pathway; subsequent (post-period) volume scale-up announced\n \n \n · \n Collaboration with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases to potentially expand Renalytix's portfolio\n \n \n Partnership with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Med...